Characterization of arsenic trioxide resistant clones derived from Jurkat leukemia T cell line: Focus on PI3K/Akt signaling pathway

Soignet, 1998, Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide, N. Engl. J. Med., 339, 1341, 10.1056/NEJM199811053391901 Chen, 2002, Expanding the use of arsenic trioxide: leukemias and beyond, Semin. Hematol., 39, 22, 10.1053/shem.2002.33611 Liu, 2003, Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies, Int. J. Hematol., 78, 32, 10.1007/BF02983237 Tabellini, 2005, Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias, Br. J. Haematol., 130, 716, 10.1111/j.1365-2141.2005.05679.x Evens, 2004, The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future, Leuk. Res., 28, 891, 10.1016/j.leukres.2004.01.011 Rojewski, 2004, Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside, Leuk. Lymphoma, 45, 2387, 10.1080/10428190412331272686 Douer, 2005, Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies, J. Clin. Oncol., 23, 2396, 10.1200/JCO.2005.10.217 Datta, 1997, Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery, Cell, 91, 231, 10.1016/S0092-8674(00)80405-5 Pap, 1998, Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway, J. Biol. Chem., 273, 19929, 10.1074/jbc.273.32.19929 Cardone, 1998, Regulation of cell death protease caspase-9 by phosphorylation, Science, 282, 1318, 10.1126/science.282.5392.1318 Kane, 1999, Induction of NF-kappaB by the Akt/PKB kinase, Curr. Biol., 9, 601, 10.1016/S0960-9822(99)80265-6 Brunet, 1999, Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor, Cell, 96, 857, 10.1016/S0092-8674(00)80595-4 Nicholson, 2002, The protein kinase B/Akt signalling pathway in human malignancy, Cell. Signal., 14, 381, 10.1016/S0898-6568(01)00271-6 Hyun, 2000, Loss of PTEN expression leading to high Akt activation in human multiple myelomas, Blood, 96, 3560, 10.1182/blood.V96.10.3560 Hayashi, 2002, Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment, Mol. Cancer Ther., 1, 851 Bornhauser, 2007, Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway, Blood, 110, 2084, 10.1182/blood-2006-12-060970 Akao, 1998, Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein, Br. J. Haematol., 102, 1055, 10.1046/j.1365-2141.1998.00869.x Chen, 1996, In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML–RAR alpha/PML proteins, Blood, 88, 1052, 10.1182/blood.V88.3.1052.1052 Passegué, 2003, Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?, Proc. Natl. Acad. Sci. USA, 100, 11842, 10.1073/pnas.2034201100 Visvader, 2008, Cancer stem cells in solid tumours: accumulating evidence and unresolved questions, Nature Rev Cancer, 8, 755, 10.1038/nrc2499 Wu, 2013, Arsenic trioxide depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of Notch pathway, Toxicol. Lett., 220, 61, 10.1016/j.toxlet.2013.03.019 Zhen, 2010, Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas, Cancer Lett., 292, 64, 10.1016/j.canlet.2009.11.005 Tomuleasa, 2010, Arsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable glioblastoma multiforme, J. BUON, 15, 758 Lunghi, 2005, Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells, Leukemia, 19, 234, 10.1038/sj.leu.2403585 Héron-Milhavet, 2002, Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage, J. Biol. Chem., 277, 15600, 10.1074/jbc.M111142200 Cossarizza, 1993, A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyanine iodide (JC-1), Biochem. Biophys. Res. Commun., 197, 40, 10.1006/bbrc.1993.2438 Vandesompele, 2002, Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes, Genome Biol., 3, 10.1186/gb-2002-3-7-research0034 Uddin, 2004, Inhibition of phosphatidylinositol 3’-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway, Biochem. Biophys. Res. Commun., 320, 932, 10.1016/j.bbrc.2004.06.038 Cully, 2006, Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis, Nat. Rev. Cancer, 6, 184, 10.1038/nrc1819 Uddin, 2006, Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival, Blood, 108, 4178, 10.1182/blood-2006-04-016907 Shan, 2000, Deficiency of PTEN in Jurkat T cells causes constitutive localization of Itk to the plasma membrane and hyperresponsiveness to CD3 stimulation, Mol. Cell. Biol., 20, 6945, 10.1128/MCB.20.18.6945-6957.2000 Choi, 2002, Arsenic trioxide-induced apoptosis in U937 cells involve generation of reactive oxygen species and inhibition of Akt, Int. J. Oncol., 21, 603 Műzes, 2012, Anti-tumor immunity, autophagy and chemotherapy, World J. Gastroenterol., 18, 6537, 10.3748/wjg.v18.i45.6537 Tokar, 2010, Arsenic-specific stem cell selection during malignant transformation, J. Natl Cancer Inst., 102, 638, 10.1093/jnci/djq093 Redondo-Muñoz, 2010, Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation, Clin. Cancer Res., 16, 4382, 10.1158/1078-0432.CCR-10-0072 Bossy-Wetzel, 1997, Induction of apoptosis by the transcription factor c-Jun, EMBO J., 16, 1695, 10.1093/emboj/16.7.1695 Leppä, 1999, Diverse functions of JNK signaling and c-Jun in stress response and apoptosis, Oncogene, 18, 6158, 10.1038/sj.onc.1203173 Potapova, 2001, Protective role for c-Jun in the cellular response to DNA damage, J. Biol. Chem., 276, 28546, 10.1074/jbc.M102075200 Wisdom, 1999, C-Jun regulates cell cycle progression and apoptosis by distinct mechanisms, EMBO J., 18, 188, 10.1093/emboj/18.1.188 Yang, 1995, Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death, Cell, 80, 285, 10.1016/0092-8674(95)90411-5 Heidari, 2012, Glucocorticoid-mediated BIM induction and apoptosis are regulated by Runx2 and c-Jun in leukemia cells, Cell Death Dis., 3, e349, 10.1038/cddis.2012.89 Whyte, 1996, ICE/CED-3 proteases in apoptosis, Trends Cell Biol., 6, 245, 10.1016/0962-8924(96)20025-X Kuida, 1995, Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme, Science, 267, 2000, 10.1126/science.7535475 Boldin, 1996, Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death, Cell, 85, 803, 10.1016/S0092-8674(00)81265-9 Whyte, 1996, A link between cell-surface receptors and ICE proteases, Trends Cell Biol., 6, 418, 10.1016/S0962-8924(96)30061-5 Singleton, 1996, Type I insulin-like growth factor receptor activation regulates apoptotic proteins, J. Biol. Chem., 271, 31791, 10.1074/jbc.271.50.31791 LeRoith, 1995, The role of the insulin-like growth factor-I receptor in cancer, Ann. N. Y. Acad. Sci., 766, 402, 10.1111/j.1749-6632.1995.tb26689.x Khandwala, 2000, The effects of insulin-like growth factors on tumorigenesis and neoplastic growth, Endocr. Rev., 21, 215, 10.1210/edrv.21.3.0399 Weber, 2002, Overexpression of the insulin-like growth factor I receptor in human colon carcinomas, Cancer, 95, 2086, 10.1002/cncr.10945 Stein, 2001, The BPS domain of Grb10 inhibits the catalytic activity of the insulin and IGF1 receptors, FEBS Lett., 493, 106, 10.1016/S0014-5793(01)02282-7 Morrione, 2003, Grb10 adapter protein as regulator of insulin-like growth factor receptor signaling, J. Cell. Physiol., 197, 307, 10.1002/jcp.10363 Dufresne, 2005, The adapter protein GRB10 is an endogenous negative regulator of insulin-like growth factor signaling, Endocrinology, 146, 4399, 10.1210/en.2005-0150 He, 1998, J. Biol. Chem., 273, 6860, 10.1074/jbc.273.12.6860 Jahn, 2002, Role for the adaptor protein Grb10 in the activation of Akt, Mol. Cell. Biol., 22, 979, 10.1128/MCB.22.4.979-991.2002 Qiu, 2000, Signaling network of the Btk family kinases, Oncogene, 19, 5651, 10.1038/sj.onc.1203958 Kawakami, 1997, Bruton’s tyrosine kinase regulates apoptosis and JNK/SAPK kinase activity, Proc. Natl. Acad. Sci. USA, 94, 3938, 10.1073/pnas.94.8.3938 Uckun, 1998, Bruton’s tyrosine kinase (BTK) as a dual-function regulator of apoptosis, Biochem. Pharmacol., 56, 683, 10.1016/S0006-2952(98)00122-1 Li, 1999, Protein kinase C-alpha overexpression stimulates Akt activity and suppresses apoptosis induced by interleukin 3 withdrawal, Oncogene, 18, 6564, 10.1038/sj.onc.1203065 Kitaura, 2000, Akt-dependent cytokine production in mast cells, J. Exp. Med., 192, 729, 10.1084/jem.192.5.729 Petro, 2000, Bruton’s tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement, J. Exp. Med., 191, 1745, 10.1084/jem.191.10.1745 Qin, 2000, Regulation of oxidative stress-induced calcium release by phosphatidylinositol 3-kinase and Bruton’s tyrosine kinase in B cells, Proc. Natl. Acad. Sci. USA, 97, 7118, 10.1073/pnas.130198197 Tseng, 2012, NADPH oxidase-produced superoxide mediates EGFR transactivation by c-Src in arsenic trioxide-stimulated human keratinocytes, Arch. Toxicol., 86, 935, 10.1007/s00204-012-0856-9 Walsh, 2002, Insulin-like growth factor-1 activates Akt and Jun N-terminal kinases (JNKs) in promoting the survival of T lymphocytes, Immunology, 107, 461, 10.1046/j.1365-2567.2002.01525.x Alao, 2007, The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention, Mol. Cancer, 6, 24, 10.1186/1476-4598-6-24 D’Amico, 2000, The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways, J. Biol. Chem., 275, 32649, 10.1074/jbc.M000643200 Zhao, 2001, Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions, J. Biol. Chem., 276, 27907, 10.1074/jbc.M104278200 Burgering, 2003, Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty, J. Leukoc. Biol., 73, 689, 10.1189/jlb.1202629 de Keizer, 2011, Forkhead box o as a sensor, mediator, and regulator of redox signaling, Antioxid. Redox Signal., 14, 1093, 10.1089/ars.2010.3403 van den Berg, 2011, Integrating opposing signals toward Forkhead box O, Antioxid. Redox Signal., 14, 607, 10.1089/ars.2010.3415 Schmidt, 2002, Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D, Mol. Cell. Biol., 22, 7842, 10.1128/MCB.22.22.7842-7852.2002 Deng, 2012, Inhibition of protein kinase C β(2) prevents tumor necrosis factor-α-induced apoptosis and oxidative stress in endothelial cells: the role of NADPH oxidase subunits, J. Vasc. Res., 49, 144, 10.1159/000332337 Diaz-Meco, 1994, Zeta PKC induces phosphorylation and inactivation of I kappa B-alpha in vitro, EMBO J., 13, 2842, 10.1002/j.1460-2075.1994.tb06578.x Romanelli, 1999, P70 S6 kinase is regulated by protein kinase Czeta and participates in a phosphoinositide 3-kinase-regulated signalling complex, Mol. Cell. Biol., 19, 2921, 10.1128/MCB.19.4.2921 Mora, 2004, PDK1, the master regulator of AGC kinase signal transduction, Semin. Cell Dev. Biol., 15, 161, 10.1016/j.semcdb.2003.12.022 Shahbazian, 2006, The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity, EMBO J., 25, 2781, 10.1038/sj.emboj.7601166